Michael E. Engel - Concepedia

Author

Michael E. Engel

Vanderbilt University ORCID

Also Known As

M E Engel, M ENGEL, M Engel, M. Engel, Michael E Engel, Michael E. Engel, Michael Engel

133

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University Boehringer Ingelheim (Germany)University of Utah Huntsman Cancer Institute University Hospital Carl Gustav Carus

About

Michael E. Engel is an author at Vanderbilt University specializing in medicine, gene expression, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.1K
2	Natural Sciences	2	2	25
3	Allergy	2	2	306
4	Health Sciences	1	1	30
5	Biochemistry	1	1	14

Michael E. Engel

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Transforming Growth Factor-β1 Mediates Epithelial to Mesenchymal Transdifferentiation through a RhoA-dependent Mechanism Neil A. Bhowmick, Mayshan Ghiassi, Andrei V. Bakin, Molecular Biology of the Cell	2001	989
Interdependent SMAD and JNK Signaling in Transforming Growth Factor-β-mediated Transcription Michael E. Engel, Maureen A. McDonnell, Brian K. Law, Journal of Biological Chemistry Transcriptional RegulationSystems BiologySignal TransductionDevelopmental BiologySignaling Pathway	1999	528
Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial Huib A.M. Kerstjens, Bernd Disse, W Schröder-Babo, Journal of Allergy and Clinical Immunology AsthmaAllergyInflammatory Lung DiseaseLung InflammationAdvanced Lung Disease	2011	275
Interaction of the Transforming Growth Factor-β Type I Receptor with Farnesyl-protein Transferase-α Masahiro Kawabata, Takeshi Imamura, Kohei Miyazono, Journal of Biological Chemistry	1995	105
RhoB Is Stabilized by Transforming Growth Factor β and Antagonizes Transcriptional Activation Michael E. Engel, Pran K. Datta, Harold L. Moses Journal of Biological Chemistry	1998	100
The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro, David Halpin, Roland Buhl, The Journal of Allergy and Clinical Immunology In Practice	2015	95
A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids Christian Vogelberg, Petra Moroni-Zentgraf, Miglė Leonavičiūtė-Klimantavičienė, Respiratory Research	2015	91
Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study Ken Ohta, Masakazu Ichinose, Yuji Tohda, PLoS ONE	2015	88
Deletion of <i>Mtg16</i>, a Target of t(16;21), Alters Hematopoietic Progenitor Cell Proliferation and Lineage Allocation Brenda Chyla, Isabel Moreno–Miralles, Melissa Ann Steapleton, Molecular and Cellular Biology Lymphocyte DevelopmentMixed-phenotype Acute LeukemiaImmunologyLineage AllocationEpigenetics	2008	79
Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype Thomas B. Casale, Eric D. Bateman, Mark Vandewalker, The Journal of Allergy and Clinical Immunology In Practice	2017	75

Page 1